Prognostic significance of CXCL12 expression in patients with colorectal carcinoma

American Journal of Clinical Pathology

Volumn 132, Issue 2, 2009, Pages 202-210

  Akishima Fukasawa, Yuri ^a   Nakanishi, Yukihiro ^a   Ino, Yoshinori ^a   Moriya, Yoshihiro ^b   Kanai, Yae ^a   Hirohashi, Setsuo ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Colorectal carcinoma; CXCL12; Immunohistochemistry; Invasive front; Prognosis

Indexed keywords

STROMAL CELL DERIVED FACTOR 1;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; CHEMOKINE CXCL12; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 68549096319     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCPK35VZJEWCUTL     Document Type: Article

References (40)

1. Ottaiano A, Franco R, Aiello Talamanca A, et al. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin Cancer Res. 2006;12:2795-2803.
2. Liotta LA, Kohn EC. The microenvironment of the tumourhost interface. Nature. 2001;411:375-379.
3. Ibe S, Qin Z, Schuler T, et al. Tumor rejection by disturbing tumor stroma cell interactions. J Exp Med. 2001;194:1549-1559.
4. Shirozu M, Nakano T, Inazawa J, et al. Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene. Genomics. 1995;28:495-500.
5. Nagasawa T, Kikutani H, Kishimoto T. Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci U S A. 1994;91:2305-2309.
6. Tashiro K, Tada H, Heilker R, et al. Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science. 1993;261:600-603.
7. Fernandis AZ, Prasad A, Band H, et al. Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene. 2004;23:157-167.
8. Nagasawa T, Tachibana K, Kishimoto T. A novel CXC chemokine PBSF/SDF-1 and its receptor CXCR4: their functions in development, hematopoiesis and HIV infection. Semin Immunol. 1998;10:179-185.
9. Salcedo R, Wasserman K, Young HA, et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1alpha. Am J Pathol. 1999;154:1125-1135.
10. Tachibana K, Hirota S, Iizasa H, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature. 1998;393:591-594.
11. Phillips RJ, Burdick MD, Lutz M, et al. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med. 2003;167:1676-1686.
12. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50-56.
13. Zeelenberg IS, Ruuls-Van Stalle L, Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res. 2003;63:3833-3839.
14. Schimanski CC, Schwald S, Simiantonaki N, et al. Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res. 2005;11:1743-1750.
15. Kaifi JT, Yekebas EF, Schurr P, et al. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst. 2005;97:1840-1847.
16. Taichman RS, Cooper C, Keller ET, et al. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002;62:1832-1837.
17. Sasaki K, Natsugoe S, Ishigami S, et al. Expression of CXCL12 and its receptor CXCR4 correlates with lymph node metastasis in submucosal esophageal cancer. J Surg Oncol. 2008;97:433-438.
18. Ishigami S, Natsugoe S, Okumura H, et al. Clinical implication of CXCL12 expression in gastric cancer. Ann Surg Oncol. 2007;14:3154-3158.
19. Jiang YP, Wu XH, Shi B, et al. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression. Gynecol Oncol. 2006;103:226-233.
20. Salmaggi A, Gelati M, Pollo B, et al. CXCL12 expression is predictive of a shorter time to tumor progression in low-grade glioma: a single-institution study in 50 patients. J Neurooncol. 2005;74:287-293.
21. Kang H, Watkins G, Parr C, et al. Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Res. 2005;7:R402-R410.
22. Sobin L, Wittekind C; for the International Union Against Cancer (UICC), eds. TNM Classification of Malignant Tumours. 6th ed. New York, NY: Wiley-Liss; 2002.
23. Hamilton SR, Aaltonen LA. Pathology and Genetics of Tumours of the Digestive System. Lyon, France: IARC Press; 2000. World Health Organization Classification of Tumours.
24. Prall F, Nizze H, Barten M. Tumour budding as prognostic factor in stage I/II colorectal carcinoma. Histopathology. 2005;47:17-24.
25. Ueno H, Price AB, Wilkinson KH, et al. A new prognostic staging system for rectal cancer. Ann Surg. 2004;240:832-839.
26. Ueno H, Murphy J, Jass JR, et al. Tumour "budding" as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology. 2002;40:127-132.
27. Okuyama T, Oya M, Ishikawa H. Budding as a risk factor for lymph node metastasis in pT1 or pT2 well-differentiated colorectal adenocarcinoma. Dis Colon Rectum. 2002;45:628-634.
28. Goldstein NS, Hart J. Histologic features associated with lymph node metastasis in stage T1 and superficial T2 rectal adenocarcinomas in abdominoperineal resection specimens: identifying a subset of patients for whom treatment with adjuvant therapy or completion abdominoperineal resection should be considered after local excision. Am J Clin Pathol. 1999;111:51-58.
29. Hase K, Shatney C, Johnson D, et al. Prognostic value of tumor "budding" in patients with colorectal cancer. Dis Colon Rectum. 1993;36:627-635.
30. Ueno H, Mochizuki H, Hashiguchi Y, et al. Predictors of extrahepatic recurrence after resection of colorectal liver metastases. Br J Surg. 2004;91:327-333.
31. Kazama S, Watanabe T, Ajioka Y, et al. Tumour budding at the deepest invasive margin correlates with lymph node metastasis in submucosal colorectal cancer detected by anticytokeratin antibody CAM5.2. Br J Cancer. 2006;94:293-298.
32. Nakamura T, Mitomi H, Kikuchi S, et al. Evaluation of the usefulness of tumor budding on the prediction of metastasis to the lung and liver after curative excision of colorectal cancer. Hepatogastroenterology. 2005;52:1432-1435.
33. Brand S, Dambacher J, Beigel F, et al. CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. Exp Cell Res. 2005;310:117-130.
34. Scotton CJ, Wilson JL, Scott K, et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res. 2002;62:5930-5938.
35. Salcedo R, Oppenheim JJ. Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation. 2003;10:359-370.
36. Mirshahi F, Pourtau J, Li H, et al. SDF-1 activity on microvascular endothelial cells: consequences on angiogenesis in in vitro and in vivo models. Thromb Res. 2000;99:587-594.
37. Phillips RJ, Mestas J, Gharaee-Kermani M, et al. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/ mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem. 2005;280:22473-22481.
38. Matteucci E, Locati M, Desiderio MA. Hepatocyte growth factor enhances CXCR4 expression favoring breast cancer cell invasiveness. Exp Cell Res. 2005;310:176-185.
39. Sullivan R, Graham CH. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev. 2007;26:319-331.
40. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999;59:5830-5835.